IDXX
Idexx Laboratories
$545.73
▼ 2.9%Updated Today 7:15 PM ET
▲ Up 8.1% over the last 12 months
Market Cap
$44.34B
P/E
40.52x
Forward P/E (est.)
32.26x
ROE
70.9%
Revenue Growth
13.1%
EPS Growth
25.6%
Profit Margin
24.6%
FCF Yield
1.9%
Debt / Equity
0.53x
ROIC
54.0%
Interest Coverage
32.71x
Current Ratio
1.12x
Dividend Yield
—
Implied Growth (rev. DCF)
6.5%
Rating Score
65/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what IDXX's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. IDXX trades near $545.73, below its 50-day average ($562.44) and 200-day average ($632.91). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 41 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. IDXX's is $16.01 (~2.9% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month IDXX found buyers near $535.95 (support) and sellers near $581.47 (resistance); its 52-week range is $506.91–$769.98. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.0× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Idexx Laboratories (IDXX) is a large-cap company in the Health Care Equipment industry, part of the Health Care sector of the S&P 500, with a market value around $44.34B.
In its latest reported year it generated about $4.30B in revenue and $1.06B in net profit.
Our model rates IDXX Favorable (65/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
7.6%
Revenue moved from $3.22B in 2021 to $4.30B in 2025, a 7.6% compound annual growth rate. The most recent year grew a steady 13.1% year over year. Consistent top-line growth is one sign of healthy demand.
Gross Margin
61.8%
Operating Margin
31.6%
Net Margin
24.6%
ROE
70.9%
Idexx Laboratories keeps about 24.6% of each sales dollar as net profit, with a 61.8% gross margin and 31.6% operating margin. Return on equity is 70.9% and return on invested capital about 54.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
$450.00M
Net Debt
$249.47M
Net Debt / EBITDA
0.18x
Debt / Equity
0.53x
Leverage: debt-to-equity is 0.5x, and operating profit covers interest about 32.7x, with a current ratio of 1.1x. That is a moderate, manageable debt load for most businesses. It carries roughly $450.00M of total debt against $200.53M of cash.
Operating CF
$1.18B
Free Cash Flow
$1.06B
FCF Margin
24.6%
In the latest year Idexx Laboratories produced about $1.18B of operating cash flow and $1.06B of free cash flow after capital spending. That is a free-cash-flow yield of about 1.9% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
40.52x
P/S
10.51x
P/B
33.01x
EV / EBITDA
30.19x
IDXX trades at 40.5x trailing earnings (about 32.3x on estimated forward earnings), 10.5x sales, and 33.0x book value. Reverse-engineering today's price implies the market expects roughly 6.5% long-term free-cash-flow growth. That is a rich multiple that prices in a lot of future growth.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How IDXX stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), IDXX ranks #12 of 59 by our overall rating. It trades at a premium versus the sector on earnings (40.5x P/E vs. 25.4x median) with a higher return on equity (70.9% vs. 14.9%) and faster revenue growth (13.1% vs. 7.9%).
P/E vs sector
40.5x
median 25.4x
ROE vs sector
70.9%
median 14.9%
Growth vs sector
13.1%
median 7.9%
Sector rank
#12
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$628.25 – $1,030.33
vs. $545.73 today · expected CAGR 3% – 14%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $4.86B | $5.50B | $6.21B | $7.02B | $7.93B |
| Net income | $1.22B | $1.37B | $1.55B | $1.75B | $1.98B |
| EPS | $15.41 | $17.42 | $19.68 | $22.24 | $25.13 |
| Share price (low) | $385.32 | $435.41 | $492.01 | $555.97 | $628.25 |
| Share price (high) | $631.92 | $714.07 | $806.90 | $911.79 | $1,030.33 |
| CAGR (low–high) | -29% / 16% | -11% / 14% | -3% / 14% | 0% / 14% | 3% / 14% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for IDXX:
- Revenue is growing 13.1% a year, a sign of real demand.
- High net margins (24.6%) point to pricing power or efficiency.
- Strong return on equity (70.9%) shows capital is put to work well.
- Our model's overall read is Favorable (65/100).
The case against IDXX:
- A rich 40.5x earnings multiple prices in a lot of growth.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Valuation risk — at 40.5x earnings, disappointing results could compress the multiple.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: Idexx Laboratories is a large-cap health care business still growing nicely, with solid profitability, and a sound balance sheet. It trades at 40.5x earnings, which our model scores Favorable (65/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.